title: Retinoid receptor alpha and Beta expression in serous ovarian tumors.
abstract: The expression of retinoid acid receptors alpha (RARalpha) and beta (RARbeta) and estrogen receptor alpha (ERalpha) was assessed by immunohistochemistry and Western blotting in normal ovaries, serous cystadenoma (n = 20), serous borderline (n = 14), and serous ovarian cancer (n = 47) and was correlated in cancer cases with stage, grade, progress-free survival (PFS), and survival. RARalpha was increasingly expressed in benign cystadenomas, borderline, and low-stage and advanced-stage neoplasms (p < 0.001). In stage III, G3 serous carcinoma, increased RARalpha expression was an independent prognostic factor associated with lower chemoresponse to first-line chemotherapy (taxol and carboplatin) and shorter PFS (p < 0.002).RARbeta and ERalpha expression did not correlate with RARalpha tumor characteristics or PFS and survival.
authors.affiliation: Department of Obstetrics and Gynecology, University Hospital of Larissa, Larissa, Greece. dapontea@otenet.gr
authors.forename: A
authors.initials: A
authors.lastname: Daponte
authors.forename: E
authors.initials: E
authors.lastname: Kostopoulou
authors.forename: C N
authors.initials: CN
authors.lastname: Papandreou
authors.forename: I
authors.initials: I
authors.lastname: Chiotoglou
authors.forename: I
authors.initials: I
authors.lastname: Voutsadakis
authors.forename: P
authors.initials: P
authors.lastname: Vanakara
authors.forename: M
authors.initials: M
authors.lastname: Minas
authors.forename: M
authors.initials: M
authors.lastname: Nakou
authors.forename: A
authors.initials: A
authors.lastname: Kallitsaris
authors.forename: P
authors.initials: P
authors.lastname: Kollia
authors.forename: G
authors.initials: G
authors.lastname: Koukoulis
authors.forename: I E
authors.initials: IE
authors.lastname: Messinis
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D015153:Blotting, Western; D018394:CA-125 Antigen / Q000097:blood; D018284:Cystadenocarcinoma, Serous / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology; D018293:Cystadenoma, Serous / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology; D018572:Disease-Free Survival; D047628:Estrogen Receptor alpha / Q000032:analysis*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000473:pathology; D011237:Predictive Value of Tests; D011379:Prognosis; D011860:Radiography, Abdominal; D018168:Receptors, Retinoic Acid / Q000032:analysis*; D000072482:Retinoic Acid Receptor alpha; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D047628:Estrogen Receptor alpha; C000607071:RARA protein, human; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; C082925:retinoic acid receptor beta